Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy.
Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124, Bari, Italy.
Eur J Med Chem. 2024 Mar 5;267:116180. doi: 10.1016/j.ejmech.2024.116180. Epub 2024 Jan 24.
Monoamine oxidases A and B (MAO A, B) are ubiquitous enzymes responsible for oxidative deamination of amine neurotransmitters and xenobiotics. Despite decades of studies, MAO inhibitors (MAOIs) find today limited therapeutic space as second-line drugs for the treatment of depression and Parkinson's disease. In recent years, a renewed interest in MAOIs has been raised up by several studies investigating the role of MAOs, particularly MAO A, in tumor insurgence and progression, and the efficacy of MAOIs as coadjutants in the therapy of chemoresistant tumors. In this survey, we highlight the implication of MAOs in the biochemical pathways of tumorigenesis and review the state-of-the-art of preclinical and clinical studies of MAOIs as anticancer agents used in monotherapy or in combination with antitumor chemotherapeutics.
单胺氧化酶 A 和 B（MAO A、B）是广泛存在的酶，负责氧化脱氨胺类神经递质和外源性物质。尽管经过几十年的研究，MAO 抑制剂（MAOIs）作为治疗抑郁症和帕金森病的二线药物，目前在治疗领域的应用仍然有限。近年来，几项研究调查了 MAOs，特别是 MAO A，在肿瘤发生和发展中的作用，以及 MAOIs 作为辅助治疗耐药肿瘤的疗效，这重新引起了人们对 MAOIs 的兴趣。在本综述中，我们强调了 MAOs 在肿瘤发生的生化途径中的作用，并回顾了 MAOIs 作为单药或与抗肿瘤化疗药物联合治疗癌症的临床前和临床研究的最新进展。
